Donepezil in more advanced Alzheimer's disease

Consultant Pharmacist

Volumn 20, Issue 7, 2005, Pages 592-600

  Rawls, W Nathan ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Donepezil; Moderate to severe AD; Nursing home

Indexed keywords

ACETYLCHOLINE; DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; BEHAVIOR CHANGE; BRADYCARDIA; CAREGIVER; CLINICAL TRIAL; COGNITION; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; HUMAN; MEDLINE; NURSING HOME; PHARMACIST; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; WEIGHT REDUCTION;

EID: 33645964276     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2005.592     Document Type: Review

References (40)

1. Evans DA, Funkenstein HH, Albert MS et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989;262:2551-6.
2. UN Population Division. World Population Ageing: 1950-2050, Executive Summary. New York, NY: Department of Economic and Social Affairs; 2002.
3. Canadian Study of Health and Aging Working Group. Patterns for caring for people with dementia in Canada. Can J Aging 1994;13:470-87.
4. Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. Am J Geriatr Psychiatry 2000;8:134-40.
5. Hill JW, Futterman R, Duttagupta S et al. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology 2002;58:62-70.
6. Cohen CA, Gold DP, Shulman KI et al. Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist 1993;33:714-20.
7. Rogers SL, Farlow MR, Doody RS et al. for the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-45.
8. Rogers SL, Doody RS, Pratt RD et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000;10:195-203.
9. Rogers SL, Doody RS, Mohs RC et al. and the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021-31.
10. Doody RS, Geldmacher DS, Gordon B et al. for the Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol 2001;58:427-33.
11. Winblad B, Engedal K, Soininen H et al. for the Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95.
12. Burns A, Rossor M, Hecker J et al. for the International Donepezil Study Group. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44.
13. Mohs RC, Doody RS, Morris JC et al. for the "312" Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-8.
14. Rosler M, Anand R, Cicin-Sain A et al. for the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-8.
15. Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
16. Farlow M, Anand R, Messina J Jr et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-41.
17. Tariot PN, Solomon PR, Morris JC et al. for the Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-76.
18. Wilcock GK, Lilienfeld S, Gaens E for the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. [published erratum appears in BMJ 2001;322:405]. BMJ 2000;321:1445-9.
19. Rockwood K, Mintzer J, Truyen L et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-95.
20. Raskind MA, Peskind ER, Wessel T et al. for the Galantamine USA-1 Study Group. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-8.
21. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-90.
22. Liston DR, Nielsen JA, Villalobos A et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. Eur J Pharmacol 2004;486:9-17.
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
24. Francis PT, Palmer AM, Snape M et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-47.
25. Feldman H, Gauthier S, Hocker J et al. for the Donepezil MSAD Study Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published erratum appears in Neurology 2001;57:2153]. Neurology 2001;57:613-20.
26. Schneider LS, Olin JT, Doody RS et al. for the Alzheimer's Disease Cooperative Study. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997;11(suppl 2):s22-s32.
27. Tariot PN, Cummings JL, Katz IR et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-9.
28. Edwards K, Goodman W, Anand R et al. Rivastigmine use in a nursing home setting. Presented at: 13th Annual Meeting of the American Association for Geriatric Psychiatry. March 12-15, 2000; Miami, Florida.
29. Salmon DP, Thal LJ, Butters N et al. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology 1990;40:1225-30.
30. Brooks JO III, Yesavage JA, Taylor J et al. Cognitive decline in Alzheimer's disease: elaborating on the nature of the longitudinal factor structure of the Mini-Mental State Examination. Int Psychogeriatr 1993;5:135-46.
31. Galasko DR, Gould RL, Abramson IS et al. Measuring cognitive change in a cohort of patients with Alzheimer's disease. Stat Med 2000;19:1421-32.
32. White H, Pieper C, Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc 1998;46:1223-7.
33. Cushman WC, Ford CE, Cutler JA et al. for the ALLHAT Collaborative Research Group. Success and predictors of Mood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404.
34. Consensus recommendations for the management of chronic heart failure. On behalt of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999;83(2A):1A-38A.
35. Clark TR. ASCP Background Paper: HCFA quality indicator on the use of nine or more medications. Available at: www.ascp.com/public/pr/ hcfabackgrounder.shtml.
36. Hill JW, Futterman R, Mastey V et al. The effect of donepezil therapy on health costs in a Medicare managed care plan. Manag Care Interface 2002;15:63-70.
37. Hendric HC. Epidemiology of dementia and Alzheimer's disease. Am J Geriatr Psychiatry 1998;6(2, suppl 1):s3-s18.
38. Evans DA. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q 1990;68:267-89.
39. Wimo A, Winblad B, Engedal K et al. for the Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial [published erratum appears in Dement Geriatr Cogn Disord 2003;16:102]. Dement Geriatr Cogn Disord 2003;15:44-54.
40. Aricept [package insert]. Teaneck, NJ: Eisai Inc.; 2004.